Please assess the completion status of the following clinical trial:

Trial Title: Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged ≥40 years with COPD diagnosis according to the current GOLD (The Global Initiative for Chronic Obstructive Lung Disease) strategy.~* Patients who have symptomatic stable moderate to severe COPD diagnosis with post-bronchodilator FEV1/FVC ratio \<0.70, and FEV1 \<80% of predicted normal at screening visit.~* Current smokers or ex-smokers with a smoking history of at least 10 pack-years~* Patients who have no exacerbation within last 4 weeks~* Female patients with childbearing potential using effective birth control method~* Patients who signed written informed consent prior to participation~* Patients who accept to comply with the requirements of the protocol~* Patients who have a capability of communicate with investigator~Exclusion Criteria:~* History of hypersensitivity to drugs contains anticholinergics, beta-adrenergic, lactose~* Diagnosis of asthma~* Patients vaccinated with live attenuated vaccines within 2 weeks prior to screening visit or during run-in period.~* Patients who had COPD exacerbation or lower respiratory track infections that required antibiotic, oral or parenteral corticosteroid treatment within 4 weeks prior to screening visit or during run-in period.~* Patients who have a history of myocardial infarction, hearth failure, acute ischemic coroner disease or severe cardiac arrhythmia requiring treatment within least 6 weeks~* Patients who have lung cancer~* Patients with active tuberculosis~* Patients who use oxygen therapy~* Patients who have common interstitial lung diseases like cystic fibrosis, bronchiolitis obliterans~* Patients with serious liver or renal disease that leads to organ failure~* Women who are pregnant or nursing~* History of allergic rhinitis and atopy~* Known symptomatic prostatic hypertrophy requiring drug therapy or operation~* Patients with narrow-angle glaucoma requiring drug therapy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tiotropium/Formoterol (Type: EXPERIMENTAL): Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
- Tiotropium (Type: ACTIVE_COMPARATOR): Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
- Tiotropium + Formoterol (Type: ACTIVE_COMPARATOR): Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler + Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer

Based on this trial design, predict the completion outcome and termination type (if applicable).